You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 30, 2025

CLINICAL TRIALS PROFILE FOR EPHEDRINE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Ephedrine Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00232817 ↗ Anesthesia and Postoperative Pain Completed Columbia University Phase 4 2003-07-01 The purpose of this study is to compare post-operative pain after anesthesia with either isoflurane or propofol. Each group will be further randomized to recieve intranasal nicotine or placebo inorder to detect potetial pronociceptive action of isoflurane. The study is a randomized, prospective, double-blinded controlled trial. Eighty adult women undergoing uterine surgery will be recruited for this study. Enrollment in this study is limited to women, because our animal studies suggest that females have a greater hyperalgesic response to volatile anesthetics than do males. The patient will be given one of two standard anesthetics for their surgery: isoflurane or propofol. We are interested in these two anesthetics because we seek to see if there exists a difference in their effects on a patient's perception of pain, as has been shown to be the case in animal studies but has not yet been studied in humans. The primary outcome variable will be postoperative pain, as measured by a numerical analog pain score (VAS) at 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 120, and 1440 minutes postoperatively. Secondary outcome measures will include morphine utilization via PCA and hemodynamics variables including heart rate, systolic BP, and diastolic BP, all of which will be measured at the same time points as the VAS score.
NCT00267332 ↗ Modafinil in Opioid Induced Sedation Terminated Sidney Kimmel Comprehensive Cancer Center Phase 3 2006-01-01 - The primary objective of this study is to evaluate the efficacy of modafinil in the treatment of opioid induced sedation as measured by the Epworth Sleepiness Scale (ESS). - The secondary objective is to estimate the frequency and severity of toxicity associated with Modafinil (400mg) in patients with opioid induced sedation.
NCT00267332 ↗ Modafinil in Opioid Induced Sedation Terminated Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Phase 3 2006-01-01 - The primary objective of this study is to evaluate the efficacy of modafinil in the treatment of opioid induced sedation as measured by the Epworth Sleepiness Scale (ESS). - The secondary objective is to estimate the frequency and severity of toxicity associated with Modafinil (400mg) in patients with opioid induced sedation.
NCT00377975 ↗ "Pecos" B-adrenergic and PPAR-G Stimulation Upregulates Lipid Metabolism in Human Subcutaneous Fat Completed Pennington Biomedical Research Center Phase 2 2003-01-01 This study compares four treatments to see which one causes the most weight loss, fat loss, loss of abdominal fat and improvement in blood tests like cholesterol. The four treatments are: Placebo, Ephedrine plus caffeine, Pioglitazone, Combined pioglitazone and ephedrine plus caffeine
NCT00426842 ↗ A Dose Response Trial Using 5 and 10 Mg of Midodrine Hydrochloride Completed James J. Peters Veterans Affairs Medical Center Phase 2 2007-01-01 With upright postures, there is an immediate redistribution of blood to the dependent circulation; venous return and central venous filling pressure are reduced, resulting in diminution of cardiac output and blood pressure. These hemodynamic alterations stimulate the baroreceptor reflex, which is mediated via the central nervous system to increase peripheral sympathetic vasomotor tone, restoring blood pressure and cardiac output within seconds-to-minutes of the assumption of the upright position. Following SCI, individuals often experience the inability to adjust to postural changes due to disruption of central command of the baroreceptor reflex and reduction in efferent sympathetic neural pathways; consequently, orthostatic hypotension (OH) and symptoms of cerebral hypo-perfusion may ensue. OH is a well-documented phenomenon, which is characterized by a fall in systolic blood pressure of >20 mmHg or diastolic BP of > 10 mmHg within 3 minutes of assumption of an upright posture. As a consequence of OH, many individuals experience symptoms of cerebral hypo-perfusion which include lightheadedness, dizziness, blurry vision, fatigue, nausea, ringing in the ears, cognitive impairment and heart palpitations. Although several investigators have reported increased prevalence of OH during the acute phase of spinal cord injury (SCI), individuals with chronic injury also experience significant falls in blood pressure with seated upright postures. This investigation will examine the effects of an alpha-agonist, midodrine hydrochloride, during head-up tilt on systemic blood pressure, cerebral blood flow and cerebral oxygenation compared to placebo administration in persons with chronic SCI who demonstrate significant orthostatic hypotension during a 24-hour observation study. This is the first study to determine the dose response and efficacy of midodrine to improve orthostatic blood pressure and cerebral blood flow and oxygenation in the SCI population.
NCT00432991 ↗ Study of the Effect of Intramuscular Ephedrine on the Incidence of Nausea and Vomiting During Elective Cesarean Section Completed New York Presbyterian Hospital Phase 2 2007-02-01 The purpose of this research study is to investigate if the incidence of nausea and vomiting that subjects experience during and after a Cesarean section can be reduced by giving a shot of the drug ephedrine into the thigh muscle at the time of spinal anesthesia administration.
NCT00432991 ↗ Study of the Effect of Intramuscular Ephedrine on the Incidence of Nausea and Vomiting During Elective Cesarean Section Completed Weill Medical College of Cornell University Phase 2 2007-02-01 The purpose of this research study is to investigate if the incidence of nausea and vomiting that subjects experience during and after a Cesarean section can be reduced by giving a shot of the drug ephedrine into the thigh muscle at the time of spinal anesthesia administration.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ephedrine Hydrochloride

Condition Name

Condition Name for Ephedrine Hydrochloride
Intervention Trials
Hypotension 24
Anesthesia 20
Cesarean Section 12
Spinal Anesthesia 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ephedrine Hydrochloride
Intervention Trials
Hypotension 67
Pain, Postoperative 29
Pre-Eclampsia 11
Vomiting 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ephedrine Hydrochloride

Trials by Country

Trials by Country for Ephedrine Hydrochloride
Location Trials
United States 106
Egypt 71
Canada 25
Turkey 21
China 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ephedrine Hydrochloride
Location Trials
New York 10
Illinois 7
California 6
Texas 5
North Carolina 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ephedrine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Ephedrine Hydrochloride
Clinical Trial Phase Trials
Phase 4 97
Phase 3 21
Phase 2/Phase 3 12
[disabled in preview] 134
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ephedrine Hydrochloride
Clinical Trial Phase Trials
Completed 144
Recruiting 48
Not yet recruiting 37
[disabled in preview] 41
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ephedrine Hydrochloride

Sponsor Name

Sponsor Name for Ephedrine Hydrochloride
Sponsor Trials
Ain Shams University 15
Mansoura University 13
Cairo University 12
[disabled in preview] 29
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ephedrine Hydrochloride
Sponsor Trials
Other 283
Industry 13
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Ephedrine Hydrochloride: Clinical Trials, Market Analysis, and Projections

Clinical Trials and Pharmacological Overview

Mechanism of Action

Ephedrine hydrochloride acts as an adrenergic receptor agonist, stimulating both alpha and beta-adrenergic receptors. This mechanism is crucial for its therapeutic effects, including increasing blood pressure, relieving bronchospasm, and acting as a decongestant and stimulant[4].

Current Clinical Trials

As of the latest updates, there are ongoing and planned clinical trials involving ephedrine hydrochloride. For instance, a clinical trial (NCT06741410) is not yet recruiting and focuses on the effect of prophylactic phenylephrine infusion, although it is not exclusively on ephedrine hydrochloride, it indicates ongoing research in related areas[4].

Pharmacokinetics

Ephedrine hydrochloride is rapidly absorbed after intramuscular or subcutaneous administration, with an immediate onset of action after intravenous administration. The duration of its pressor and cardiac responses is approximately 1 hour. It is primarily excreted unchanged in the urine, with a plasma half-life of 3 to 6 hours, which can be influenced by the pH of the urine[1].

Market Analysis

Market Size and Growth

The ephedrine hydrochloride market is experiencing significant growth. As of 2023, the market size was valued at USD 100 billion and is projected to reach USD 147.74 billion by 2031, growing at a compound annual growth rate (CAGR) of 5% from 2024 to 2031[5].

Regional Market Dynamics

  • North America: This region is a major driver of the ephedrine hydrochloride market, driven by increasing demand for weight loss and athletic performance enhancement products[3][5].
  • Europe: Europe is the fastest-growing region, with rising consumer interest in weight control and performance enhancement products despite stringent regulatory controls[3].
  • Asia-Pacific: This region holds a significant share of the global market, with a projected CAGR of 7.00% from 2024 to 2031. The growing health consciousness and incidence of respiratory illnesses are key factors[3][5].
  • Latin America and Middle East & Africa: These regions are also experiencing growth, with Latin America projected to grow at a CAGR of 4.4% and the Middle East & Africa at a CAGR of 4.7% from 2024 to 2031[3].

Application Segments

The market is segmented based on various applications:

  • Bronchodilator: Ephedrine hydrochloride is widely used for treating bronchial asthma and other respiratory conditions by relaxing airway muscles[3][5].
  • Decongestant: It is used to relieve nasal congestion.
  • Stimulant: Used in weight loss and athletic performance enhancement products.
  • Spinal Anesthesia Induced Hypotension: Ephedrine acts as a vasoconstrictor to stabilize blood pressure during anesthesia procedures[3].

Distribution Channels

Hospital pharmacies play a crucial role in the distribution of ephedrine hydrochloride, providing medications and supplements for various medical settings, including anesthesia and respiratory treatments[3].

Market Projections

Driving Factors

Several factors are driving the growth of the ephedrine hydrochloride market:

  • Increasing Demand for Respiratory Treatments: Rising rates of respiratory illnesses such as asthma and COPD are fueling the demand for efficient bronchodilators[5].
  • Improvements in Medication Formulations: Advances in drug delivery technologies and the development of new formulations are enhancing the market[5].
  • Growing Health Consciousness: Increased focus on health and wellness globally is driving the demand for dietary supplements and medications containing ephedrine hydrochloride[5].
  • Regulatory Approvals: Regulatory approvals for novel formulations and the growth in over-the-counter (OTC) medicine sales are supporting market expansion[5].

Challenges and Regulatory Landscape

Despite the growth, the market faces challenges such as regulatory scrutiny and concerns over safety and efficacy. The COVID-19 pandemic also had a varied impact, with initial disruptions in supply chains and heightened regulatory scrutiny affecting the market[3].

Key Takeaways

  • Clinical Trials: Ongoing research and clinical trials are focused on optimizing the use of ephedrine hydrochloride.
  • Market Growth: The ephedrine hydrochloride market is projected to grow significantly, driven by increasing demand in pharmaceutical and supplement sectors.
  • Regional Dynamics: North America, Europe, and the Asia-Pacific region are key drivers of the market.
  • Application Segments: The market is segmented into bronchodilators, decongestants, stimulants, and treatments for spinal anesthesia-induced hypotension.
  • Distribution Channels: Hospital pharmacies are pivotal in the distribution of ephedrine hydrochloride products.

FAQs

What is the primary mechanism of action of ephedrine hydrochloride?

Ephedrine hydrochloride acts as an adrenergic receptor agonist, stimulating both alpha and beta-adrenergic receptors.

What are the main applications of ephedrine hydrochloride?

Ephedrine hydrochloride is used as a bronchodilator, decongestant, stimulant, and for treating spinal anesthesia-induced hypotension.

Which regions are driving the growth of the ephedrine hydrochloride market?

North America, Europe, and the Asia-Pacific region are the key drivers of the market.

What are the projected market size and growth rate for ephedrine hydrochloride?

The market size is projected to reach USD 147.74 billion by 2031, growing at a CAGR of 5% from 2024 to 2031.

What are the main factors driving the growth of the ephedrine hydrochloride market?

Increasing demand for respiratory treatments, improvements in medication formulations, growing health consciousness, and regulatory approvals are key drivers.

Sources

  1. Extract from the Clinical Evaluation Report for Ephedrine Hydrochloride - Therapeutic Goods Administration.
  2. Ephedrine Hydrochloride Market Size, Share, Growth & Trends - Verified Market Reports.
  3. Global Ephedrine market size - Cognitive Market Research.
  4. Ephedrine Hydrochloride - Drug Targets, Indications, Patents - Synapse.
  5. Ephedrine Hydrochloride Market Size and Projections - Market Research Intellect.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.